Below is a summary of our recent news. Click any post title or the read more link below any story to see more!
A company based in England and Belgium has started enrolling patients for a Phase I clinical trial for a new Graves' disease therapy - we will definitely be watching this development very closely! Click here to read more.
ThyCa: Thyroid Cancer Survivors’ Association, Inc. has generously offered the GDATF an opportunity to do a seminar on Graves' disease during the 19th International Thyroid Cancer Survivors' Conference at the Hilton Los Angeles Airport Hotel! The event will take place on Saturday, October 22nd from 12:30 - 5:30 p.m. and will feature presentations from Dr. Raymond Douglas, Dr. Ira Lesser, and Dr. Andrew Gianoukakis.
Please click here to register!
If you or a loved one is a thyroid cancer survivor and you would like to register for the entire conference, please click here for registration info. The cost to attend the full ThyCa conference is $50, with scholarships available to those with financial need. A huge thank you to THYCA for the opportunity - you can read more about their programs and services here: http://www.thyca.org/
Have you asked your endocrinologist about the American Thyroid Association's new guidelines for the management of hyperthyroidism?
“These ATA guidelines, written by an international and multidisciplinary task force, provide a significant update compared to the previous version published in 2011 because they integrate recent studies and developments in practice trends,” says Peter A. Kopp, MD, Editor-in-Chief of Thyroid and Associate Professor of Medicine, Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago.
Task force chair Douglas Ross, MD, Massachusetts General Hospital, Boston, MA notes, “Some of the highlights of the 2016 guidelines are the changing paradigms for the evaluation and management of Graves’ disease with more reliance upon the measurement of thyrotropin receptor antibodies, new approaches for managing hyperthyroid patients desiring pregnancy, new approaches in the management of calcium metabolism prior to thyroid surgery, and a critical re-evaluation of the long-term toxicity of antithyroid drugs.”
Concerned about low energy?...Memory loss?...Fatigue?...Depression? … Rapid heartbeat?…Restlessness?…Infertility?... Weight or hair changes?… A lump on your neck?... Could it be your thyroid?
The American Thyroid Association and the ATA Alliance for Patient Education (including the GDATF) will host a special patient forum in Denver, CO on Saturday, September 24 from 2:30 pm – 4:30 pm Denver, Colorado. Location: Governor’s Square 14 Room, Plaza Building, Concourse Level Sheraton Denver Downtown Hotel 1550 Court Place, Denver, CO 80202. This program is free and all are welcome, including walk-in-attendees; however, reservations are encouraged to ensure we have enough seating. To RSVP, please e-mail ThyCa at [email protected] To view the meeting flyer, please click here.
LA BioMed is currently recruiting individuals aged 18-64 with a diagnosis of Graves' disease who are not currently on methimazole or PTU for a clinical trial testing an experimental immunologic therapy. Individuals who qualify will be financially compensated for their time. Interested individuals should contact the Thyroid Research Unit at LA BioMed at (310) 222-8172. For more information, visit clinicaltrials.gov and enter the following trial identifier in the search box: NCT02713256.